Latest Sipuleucel-T Stories
Emerging Therapies to Treat Metastatic Hormone-Refractory Prostate Cancer Will Capture More Than One-Third of the Market, According to a New Report from Decision Resources WALTHAM, Mass., July 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that $2 billion growth in the prostate cancer drug market though 2018 will be driven principally by the launch of emerging therapies in the metastatic...
SAN FRANCISCO, June 1 /PRNewswire/ -- The markets closed out May in positive territory following on from their April performance...which was their best month in nine years.
SEATTLE, May 13 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced today the closing of its previously reported underwritten public offering of 10,700,000 shares of its common stock, which shares were offered for sale to the public at $19.20 per share.
SEATTLE, May 8 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced today the pricing of an underwritten public offering of 10,700,000 shares of its common stock. Deutsche Bank Securities will act as sole manager for the offering.
SEATTLE, May 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the first quarter ended March 31, 2009. Revenue for the first quarter of 2009 was $30,000 compared to $31,000 for the quarter ended March 31, 2008.
U.S. scientists have determined sipuleucel-T, a prostate cancer immunotherapy drug, significantly prolongs survival in men with advanced prostate cancer. A Phase 3 trial showed sipuleucel-T (Provenge) improved survival in men with metastatic disease.
VALLEY COTTAGE, N.Y., April 30 /PRNewswire/ -- Less than two weeks ago, early on April 15th, Stock Preacher, in their Stock Talk section, posted a Special Technical Report on Dendreon Corporation (Nasdaq: DNDN), which we have been watching since 2007, when we first learned about it.
According to a report released on Tuesday, a new approach to fighting prostate cancer extended the lives of men suffering from the disease.
Phase 3 IMPACT Trial Results to be presented during late-breaking session at AUA Annual Scientific Meeting CHICAGO, April 28 /PRNewswire-USNewswire/ -- Sipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be presented April 28 at the American Urological Association (AUA) Annual Scientific Meeting in Chicago.
- Extended Median Survival by 4.1 Months and Increased 3-Year Survival by 38 Percent Compared to Placebo - - First Active Cellular Immunotherapy for Cancer to Prolong Survival - - Company to Host Webcast at 5:30 pm ET - CHICAGO and SEATTLE, April 28 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that its pivotal Phase 3 IMPACT study of PROVENGE(R) (sipuleucel-T) in men with advanced prostate cancer met its primary endpoint of significantly improving overall...
- A transitional zone between two communities containing the characteristic species of each.